SAN FRANCISCO, CA — June 16, 2002 —
The addition of rosiglitazone to glyburide/metformin tablets appears to be an effective option for lowering hemoglobin A1c (HbA1c) and fasting plasma glucose levels and achieving recommended glycemic targets in diabetic patients not otherwise controlled with standard dual combination therapy.
These results were presented here Friday at the 62nd Scientific Sessions of the American Diabetes Association (ADA). Dr. Barry J. Goldstein, with Jefferson Medical College in Philadelphia, Pennsylvania, and co-workers evaluated the efficacy and safety of adding rosiglitazone to an established regimen of glyburide/metformin in patients who had diabetes for a mean of nine years.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!